These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16033841)

  • 1. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
    Febbo PG; Richie JP; George DJ; Loda M; Manola J; Shankar S; Barnes AS; Tempany C; Catalona W; Kantoff PW; Oh WK
    Clin Cancer Res; 2005 Jul; 11(14):5233-40. PubMed ID: 16033841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
    Ross RW; Galsky MD; Febbo P; Barry M; Richie JP; Xie W; Fennessy FM; Bhatt RS; Hayes J; Choueiri TK; Tempany CM; Kantoff PW; Taplin ME; Oh WK
    Cancer; 2012 Oct; 118(19):4777-84. PubMed ID: 22282219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
    Vuky J; Porter C; Isacson C; Vaughan M; Kozlowski P; Picozzi V; Corman J
    Cancer; 2009 Feb; 115(4):784-91. PubMed ID: 19130458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
    Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
    Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
    Chi KN; Chin JL; Winquist E; Klotz L; Saad F; Gleave ME
    J Urol; 2008 Aug; 180(2):565-70; discussion 570. PubMed ID: 18554663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
    Kim WY; Whang YE; Pruthi RS; Baggstrom MQ; Rathmell WK; Rosenman JG; Wallen EM; Goyal LK; Grigson G; Watkins C; Godley PA
    Urol Oncol; 2011; 29(6):608-13. PubMed ID: 20022268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
    Oh WK; George DJ; Kaufman DS; Moss K; Smith MR; Richie JP; Kantoff PW
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):40-4. PubMed ID: 11685727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
    Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
    Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
    Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
    Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
    Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
    J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers.
    Berger AP; Niescher M; Fischer-Colbrie R; Pelzer A; Bartsch G; Horninger W
    Urol Int; 2004; 73(2):110-2. PubMed ID: 15331892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
    Narita S; Tsuchiya N; Kumazawa T; Maita S; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Nanjyo H; Habuchi T
    World J Surg Oncol; 2012 Jan; 10():1. PubMed ID: 22214417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
    Kibel AS; Rosenbaum E; Kattan MW; Picus J; Dreicer R; Klein EA; Chatta GS; Nelson JB; DiPaola RS; Roth BJ; Cookson MS; Wilding G; Jarrard DF; Beer TM; Ryan CW; Petrylak DP; Benson MC; Partin AW; Garrett-Mayer E; Eisenberger MA
    J Urol; 2007 May; 177(5):1777-81. PubMed ID: 17437819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T; Sacco E; Pagano F; Gardiman M; Cisternino A; Betto G; Sperandio P
    BJU Int; 2007 Aug; 100(2):274-80. PubMed ID: 17355369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
    Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
    Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
    Womble PR; VanVeldhuizen PJ; Nisbet AA; Reed GA; Thrasher JB; Holzbeierlein JM
    J Urol; 2011 Sep; 186(3):882-7. PubMed ID: 21791342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
    Galsky MD; Xie W; Nakabayashi M; Ross RW; Fennessy FM; Tempany CM; Choueiri TK; Khine K; Kantoff PW; Taplin ME; Oh WK
    Prostate Cancer Prostatic Dis; 2013 Sep; 16(3):266-70. PubMed ID: 23712318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
    Dreicer R; Magi-Galluzzi C; Zhou M; Rothaermel J; Reuther A; Ulchaker J; Zippe C; Fergany A; Klein EA
    Urology; 2004 Jun; 63(6):1138-42. PubMed ID: 15183967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
    Vuky J; Corman JM; Porter C; Olgac S; Auerbach E; Dahl K
    Oncologist; 2013 Jun; 18(6):687-8. PubMed ID: 23740935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
    Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
    J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.